Chongqing Zhifei Biological Products' (SHE:300122) subsidiary, Beijing Zhifei Lvzhu Biopharmaceutical, received approval from China's National Medical Products Administration for the clinical trial of its recombinant rotavirus subunit vaccine, according to a Monday disclosure with the Shenzhen bourse.
The vaccine will be tested for its ability to prevent acute gastroenteritis caused by rotavirus infection.
The drugmaker's shares rose nearly 1% during the afternoon trade.